EGFR and non-small cell lung carcinoma: Earlier reports have shown that vorinostat is effective in correcting splicing in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) cell lines harboring the BIM deletion polymorphism, and overcoming BIM deletion polymorphism-mediated EGFR TKI resistance [9].